menu
    • menu

    Company profile for C-Ray Therapeutics

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    C-Ray Therapeutics is an innovative biopharmaceutical company devoted to the development, manufacturing, clinical application and commercialization of radiopharmaceuticals. Based on the portfolio around life-threatening diseases such as oncology, we are bringing innovation to the development and commercialization of radiopharmaceuticals to address patients’ unmet clinical needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    C-Ray TherapeuticsChina Flag
    Country
    Country
    China
    Address
    Address
    No. 319 Qingpi Boulevard, Wenjiang District, Chengdu
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.c-raytherapeutics.com/en/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Product Expo West

    Natural Product Expo West

    Not Confirmed

    envelop Contact Supplier

    Natural Product Expo West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    C-Ray Gains AAALAC Full Accreditation
    C-Ray Gains AAALAC Full Accreditation

    24 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/c-ray-therapeutics-achieves-aaalac-international-full-accreditation-reinforcing-commitment-to-excellence-in-preclinical-research-302695472.html

    PR NEWSWIRE
    24 Feb 2026
    Share Share
    C-Ray Therapeutics Congratulates Biokin Pharma On NMPA Approval
    C-Ray Therapeutics Congratulates Biokin Pharma On NMPA Approval

    12 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/c-ray-therapeutics-chengdu-co-ltd-congratulates-partner-biokin-pharmaceutical-on-nmpa-ind-approval-of-first-proprietary-arc-drug-177lu-bl-arc001-302581321.html

    PR NEWSWIRE
    12 Oct 2025
    Share Share
    C-Ray Therapeutics Presents 225Ac-PSMA-CY313 Data At EANM 2025
    C-Ray Therapeutics Presents 225Ac-PSMA-CY313 Data At EANM 2025

    08 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/c-ray-therapeutics-shanghai-co-ltd-presents-breakthrough-clinical-data-of-novel-targeted-alpha-therapy-225ac-psma-cy313-at-eanm-2025-302578449.html

    PR NEWSWIRE
    08 Oct 2025
    Share Share
    C-Ray Backs Mednovo Ph 3 Trial, First Patient Dosed With 177Lu
    C-Ray Backs Mednovo Ph 3 Trial, First Patient Dosed With 177Lu

    10 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/c-ray-therapeutics-supports-mednovos-phase-iii-clinical-trial-with-first-patient-dosed-for-lutetium-177lu-oxodotreotide-injection-302552536.html

    PR NEWSWIRE
    10 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search